We have developed tools to evaluate biomarkers for prognostic enrichment of clinical trials. Enriching clinical trials with prognostic biomarkers can help trials to better evaluate an intervention in a patient population with a higher rate of the unwanted event than the broader patient population. This higher event rate translates to a lower sample size for the clinical trial. Our methodology has been implemented for trials with dichotomous/binary outcomes (BioPET) and for trials with survival/time-to-event outcomes (BioPETsurv). More details regarding BioPET can be found in the Clinical Trials paper: Evaluating biomarkers for prognostic enrichment of clinical trials. Additional information about BioPETsurv can be found in the PLoS One paper: BioPETsurv: Methodology and open source software to evaluate biomarkers for prognostic enrichment of time-to-event clinical trials.
We have worked with SomaLogic, a protein biomarker discovery and clinical diagnostics company. We have compared several blood and urine proteins by immunoassay method and aptamer method (SomaLogic), the results of which can be found here (see updated supplementary figures). Further details regarding the assays and measurements can be found here.